Physician profile
Kalid Adab
NPI 1346473345
$7,159.34
in general payments reported to CMS, 2019-2025
45 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,792 · 2020: $652 · 2021: $166 · 2022: $395 · 2023: $1,774 · 2024: $1,909 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,970 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.07 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $836.08 | 2019-2024 | Venclexta, Tecentriq, Alecensa |
| Amgen INC. | $688.25 | 2019-2024 | Kyprolis, Lumakras, Blincyto |
| Novartis Pharmaceuticals Corporation | $523.14 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $492.42 | 2019-2024 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $487.49 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Lilly USA, LLC | $395.31 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $330.30 | 2019-2024 | Lynparza, Enhertu |
| Gilead Sciences, INC. | $278.48 | 2022-2024 | Trodelvy |
| Janssen Biotech, INC. | $258.42 | 2020-2025 | Rybrevant, Tecvayli, Talvey |
| Incyte Corporation | $257.09 | 2019-2025 | Jakafi |
| Celgene Corporation | $210.51 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $184.32 | 2022-2024 | Enhertu |
| Pfizer INC. | $175.16 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $152.15 | 2025 | Darzalex, Tecvayli, Carvykti |
| Ipsen Biopharmaceuticals, INC | $140.06 | 2019-2024 | Onivyde, Tazverik |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $132.67 | 2023-2024 | Cabometyx |
| Sobi, INC | $130.34 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $126.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.69 | 2023-2025 | Ninlaro |
| Pharmaessentia USA Corporation | $99.67 | 2023-2024 | Besremi |
| Eisai INC. | $97.01 | 2023-2024 | |
| Genzyme Corporation | $91.75 | 2019-2024 | |
| Dova Pharmaceuticals | $91.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $89.19 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Mirati Therapeutics, INC. | $71.01 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $70.82 | 2022-2024 | Libtayo |
| Abbvie INC. | $64.46 | 2022-2025 | Creon |
| Emd Serono, INC. | $59.39 | 2023-2024 | Bavencio |
| Seagen INC. | $54.45 | 2023 | Adcetris |
| Puma Biotechnology, INC. | $40.95 | 2024 | |
| Beigene USA, INC. | $39.83 | 2023 | Brukinsa |
| Roche Diagnostics Corporation | $39.31 | 2019 | |
| Adaptive Biotechnologies Corporation | $39.01 | 2024 | Clonoseq |
| Teva Pharmaceuticals USA, INC. | $35.47 | 2019 | |
| Ge Healthcare | $32.25 | 2023 | |
| Array Biopharma INC | $29.16 | 2024 | Braftovi, Mektovi |
| Fisher & Paykel Healthcare INC | $27.27 | 2019 | |
| Taiho Oncology, INC. | $27.01 | 2024 | |
| Inari Medical, INC. | $26.26 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Coherus Oncology, INC. | $25.28 | 2022 | |
| Novo Nordisk INC | $24.76 | 2019 | |
| Morphosys, US INC. | $22.40 | 2023 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $21.87 | 2024 | Ultomiris |
| Adc Therapeutics America, INC. | $19.98 | 2022 | |
| Shire North American Group INC | $15.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalid Adab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.